36873-42-4

Upstream product

• 74-96-4 ethyl bromide 
• 36867-19-3 (4,4,6-trimethyl-5,6-dihydro-4H-[1,3]oxazin-2-yl)-acetic acid ethyl ester 
• 6776-19-8 ethyl (Z)-crotonate 
• 201230-82-2 carbon monoxide 
• 72653-56-6 (Z)-(1-ethoxybut-1-enyloxy)trimethylsilane 
• 68-12-2 N,N-dimethyl-formamide 
• 623-70-1 ethyl (E)-crotonate 
• 69263-38-3 2-diethoxymethyl-butyric acid ethyl ester 
• 7664-93-9 sulfuric acid 
• 623-42-7 butanoic acid methyl ester 
• 109-94-4 formic acid ethyl ester 
• 105-54-4 butanoic acid ethyl ester 
• 99437-71-5 ethyl 2-(hydroxymethyl)butanoate 

Downstream Products

• 607714-39-6 2-(benzyloxyimino-methyl)-butyric acid ethyl ester 
• 4212-49-1 5-ethyluracil 
• 1279062-68-8 (R)-2-(4-tert-butylphenoxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one 
• 1279015-81-4 (S)-6-ethyl-2-(3-iodophenoxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one 
• 1279014-78-6 (S)-6-ethyl-2-(2'-methylbiphenyl-4-yloxymethyl)-2,3-dihydrooxazolo[3,2-a]pyrimidin-7-one 
• 1279016-00-0 (S)-6-ethyl-2-(methyl-biphenyl-4-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one 
• 1279014-74-2 (S)-2-(biphenyl-4-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one 
• 1279014-64-0 (S)-2-(2',3'-dimethylbiphenyl-4-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one 

Relevant academic research and scientific papers

1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES

The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Diastereospecific nazarov cyclization of fully substituted dienones: Generation of vicinal all-carbon-atom quaternary stereocenters

No vacancy: Fully substituted dienones that are highly polarized by a vinylogous carbonate group were found to undergo a remarkably rapid and diastereospecific Nazarov cyclization that led to cyclopentenones with vicinal all-carbon-atom quaternary centers (see example; SEM=2-(trimethylsilyl) ethoxymethyl, Tf=trifluoromethanesulfonyl). Copyright

Neutral nazarov-type cyclization catalyzed by palladium(0)

Joining the circle: The first Pd0 catalyzed Nazarov-type cyclization of diketoesters (see scheme) proceeds in 70 % to 95 % yield under strictly neutral pH conditions. Aryl substitution of the diketoesters is not required, so the reaction shows great versatility and can also proceed with aliphatic substrates. Copyright

SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of

SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds

SUBSTITUTED PHENOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted phenoxymethyl dihydro oxazolopyrimidinones of formula (I) defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invent

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS

The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE

The present invention is to provide a process for simply producing an optically active 3-hydroxypropionic ester derivative useful as a medicament intermediate from an inexpensive material. More specifically, the present invention is directed to a process for producing an optically active 3-hydroxypropionic ester derivative comprising reacting an acetic ester derivative available at low cost with a base and a formic ester, thereby converting the acetic ester derivative into a 2-formylacetic ester derivative, and thereafter, stereospecifically reducing the formyl group of the derivative by use of an enzymatic source capable of stereoselectively reducing the formyl group of the derivative.